ARRHYTHMIA DETECTION/ALARM DEVICE CLASS II CONSIDERATION RECOMMENDED
This article was originally published in The Gray Sheet
Executive SummaryARRHYTHMIA DETECTION/ALARM DEVICE CLASS II CONSIDERATION RECOMMENDED by the Health Industry Manufacturers Association in comments on FDA's proposed strategy to call for premarket approval applications for remaining preamendment Class III devices. In an Aug. 31 letter written for HIMA by the Washington, D.C. law offices of King & Spaulding, the association says FDA should include the devices with those the agency thinks have "a high potential for reclassification."
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.